Jazz in tune with Zymeworks’ biliary cancer data, opts in for $325M

A data readout this week that could position Zymeworks’ antibody as the first approved HER2-targeted therapy for biliary tract cancers has cemented Jazz’s deal for most of its worldwide rights.

Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) said it will pay $325 million to exercise an option for zanidatamab, a biparatopic antibody targeting two distinct epitopes of HER2, under an October deal with Zymeworks Inc. (NASDAQ:ZYME)...